Avalo Therapeutics is a biopharmaceutical company. Co.'s rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for therapies for congenital disorders of glycosylation and CERC-006, an oral mTORC1/2 inhibitor in development for the treatment of complex lymphatic malformations. Co. is also developing two monoclonal antibodies. CERC-002, which targets the cytokine LIGHT and is in clinical development for the treatment of severe pediatric-onset Crohn's disease and COVID-19 acute respiratory distress syndrome; and CERC-007, which targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease and multiple myeloma. The AVTX stock yearly return is shown above.
The yearly return on the AVTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AVTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|